Who are Hologic’s competitors?
Hologic names 10 companies as competitors in its latest annual report, on 5 fronts. 4 companies name Hologic back.
Skip to the field, head to head ↓Hologic company profile
Hologic's Diagnostics rival also supplies it with key raw materials
Most rivalries play out at the customer. This one also runs through the supply room. Hologic calls Roche "a direct competitor of our Diagnostics business". It also calls Roche "our current supplier of certain key raw materials for certain of our amplified NAT diagnostic assays". One company holds both roles.
The rest of Hologic's field is simpler, and it is mostly about size. Hologic took in $4.1 billion, grew 2%, and kept a 14% net margin. Its named surgical rivals are "large, full suite surgical solutions companies". Johnson & Johnson brought in $94.2 billion and Medtronic $36.4 billion. Those rivals can bundle. Hologic has to win on narrower ground.
So the idea to repeat: Hologic's most tangled competitor is the one it buys from. Nothing here says the arrangement is strained. But the usual map of rivals by market misses it. Ask what each rival sells to you, as well as what it sells against you.
Where Hologic says it competes
“our primary competitors include Roche Diagnostics, Abbott Laboratories and Cepheid in the molecular diagnostics field, and Becton Dickinson in the cytology field”
“a direct competitor of our Diagnostics business”
“our current supplier of certain key raw materials for certain of our amplified NAT diagnostic assays”
“our primary competitors are large imaging companies such as Siemens Healthineers and GE Healthcare”
“our primary competitors are large, full suite surgical solutions companies such as Johnson & Johnson and Medtronic”
Who names Hologic as a competitor
“These companies include Agendia Inc., Veracyte, Inc., Myriad Genetics, Inc., and Hologic, Inc.”
10-K for 2025“Our primary competitors in our oncology market are BD, Hologic, Inc., Argon Medical Devices, Inc. and Cook Medical.”
10-K for 2025“Some of our principal competitors include, among others, Abbott Laboratories, bioMérieux, Bio-Rad, Danaher, Diasorin, Hologic, Qiagen, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Waters Corporation (acquired BD Diagnostics division) and Wermerson Immuncor.”
10-K for 2025“Larger companies such as Johnson & Johnson, Baxter International, Medtronic and Hologic have offerings that compete with our medical device products.”
10-K for 2025The field, from the filings
| Company | Fiscal year | Revenue | Growth | Net margin | Employees |
|---|---|---|---|---|---|
| Hologic | FY to Sep 2025 | $4.1B | +2% | 14% | 7,070 |
| Johnson & Johnson | 2025 | $94.2B | +6% | 28% | – |
| Abbott Laboratories | 2025 | $44.3B | +6% | 15% | – |
| Medtronic | FY to Apr 2026 | $36.4B | +8% | 13% | – |
| Becton Dickinson | FY to Sep 2025 | $21.8B | +8% | 8% | – |
| GE HealthCare Technologies | 2025 | $20.6B | +5% | 10% | 10,300 |
| Cooper Companies | FY to Oct 2025 | $4.1B | +5% | 9% | – |
| Exact Sciences | 2025 | $3.2B | +18% | −6% | 7,200 |
| QuidelOrtho | 2025 | $2.7B | −2% | −41% | 6,500 |
| Merit Medical Systems | 2025 | $1.5B | +12% | 8% | 7,500 |
Each company’s latest fiscal year as reported to the SEC, in US dollars; fiscal years end in different months. Rivals that report outside the US or in other currencies are not shown.
How concentrated Hologic’s customers are
“In fiscal 2025, 2024, and 2023, no customer accounted for more than 10% of our consolidated revenues.”
“There were no customers that represented greater than 10 % of consolidated revenues for fiscal years 2025, 2024 and 2023 .”
What the rivals have done lately
“The Interventional Solutions franchise achieved sales of $6.4 billion in 2023, representing an increase of 47.7% from 2022, which includes sales from Abiomed acquired on December 22, 2022.” filing
“The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately $14.5 billion which closed on April 2, 2025, and for general corporate purposes.” filing
“On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott's efforts to develop connected solutions for making diabetes management more personal and precise.” filing
“On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $ 20 per common share, which equated to a purchase price of $ 851 million.” filing
“On April 20, 2026, the Company acquired all the remaining outstanding shares of CathWorks Ltd. (CathWorks), a privately held medical device company, for $525 million of consideration transferred, including $115 million of contingent cons…” filing
“On June 12, 2026, the Company closed on the acquisition of all outstanding shares of Scientia Vascular (Scientia) (a privately held company).” filing
“On September 3, 2024, BD completed the acquisition of Critical Care, which was renamed as BD Advanced Patient Monitoring.” filing
“On September 3, 2024, BD completed the acquisition of Edwards Lifesciences’ Critical Care product group, which was renamed as BD Advanced Patient Monitoring.” filing
“On February 17, 2023, the Company acquired 100 % of the stock of Caption Health, Inc. (“Caption Health”) for $ 127 million of upfront payment, $ 10 million of future holdback payment, and potential earn-out payments valued at $ 13 millio…” filing
“(2) Includes the acquisition of IMACTIS SAS in the second quarter of 2023.” filing
Decisions that shaped the field
| Medtronic Bought Its Way Into Everything. The Market Just Asked It to Stop. | 2025 | Never undone |
Asked about Hologic’s competitors
Who are Hologic's competitors?
In its annual report for fiscal 2025, Hologic names 10 competitors across 5 fronts: diagnostics competitors, direct competitors of diagnostics business, current supplier of key raw materials, large imaging companies and large full-suite surgical solutions companies. 10-K for fiscal 2025
Which companies name Hologic as a competitor?
4 companies in our coverage name it in their own annual reports: Exact Sciences, Merit Medical Systems, QuidelOrtho and Cooper Companies.
How does Hologic compare with its rivals?
Hologic reported $4.1B in revenue in its latest fiscal year, +2% on a year, with a 14% net margin. Johnson & Johnson: $94.2B, 28% net margin; Abbott Laboratories: $44.3B, 15% net margin.
What are the alternatives to Hologic?
The companies Hologic itself names as competitors are listed above, front by front, each in its own report’s words. Which matters for a given buyer depends on the job, not the list.
How much of your revenue comes from somebody who is also trying to replace you?
Sources: Hologic’s annual report for fiscal 2025; the annual reports of the companies that name it; each company’s financial data as reported to the SEC; Stratrix Decision Records. Analysis and data, not advice.
Keep going
For information and strategic analysis only, not investment advice. Stratrix does not recommend buying, selling or holding any security.
Tools to try
- Ansoff move finderFramework: Ansoff Matrix
- Business model canvas builderFramework: Business Model Canvas
- Change readiness checkFramework: Kotter's 8-Step Change Model
- Five Forces scorerFramework: Porter's Five Forces
- SMART goal builderFramework: SMART Goals
- SWOT builderFramework: SWOT Analysis
More from Stratrix
The Business Model Wizard
Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.
Free · about twelve minutesBuild your Model Thesis →Test a decision, free
Set a live decision against the companies that made it before you.
AcquisitionsThe Distance TestDivestituresThe Divestiture TestDiversificationThe Diversification TestMake or buyThe Make-or-Buy TestWeekly email
Stratonomics, every Tuesday
One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.